Coca-Cola Q4 Revenue Up 6% on Strong Sales “`

Coca-Cola (NYSE:KO) reported a 6% revenue increase in the fourth quarter, overcoming prior sales volume declines. Despite challenges like increased costs from U.S. aluminum tariffs, Coca-Cola is confident in its capacity to navigate these obstacles while innovating and expanding globally. Coca-Cola's Revenue Growth Outpaces Economic Headwinds President Trump's increase of…

ILIKOS and JCPR Partner to Streamline Bioequivalence/Bioavailability Studies in Jordan

PAPHOS, Cyprus, Feb. 11, 2025 — ILIKOS Consulting Group and the Jordan Center for Pharmaceutical Research (JCPR) have formed a strategic partnership to showcase the benefits of designing and conducting BE/BA studies in Jordan, thereby advancing innovative clinical research nationwide. Partnership Objectives: Highlight the advantages of performing BA/BE clinical trials…

Knightscope’s Renewals Generate Over $1 Million in Annual Recurring Revenue “`

Lake Street Capital Markets Initiates Coverage MOUNTAIN VIEW, Calif.–February 10, 2025– (NASDAQ:KSCP), a robotics and artificial intelligence technology company specializing in public safety solutions, has renewed contracts for 7 Autonomous Security Robots (ASRs) and 14 K1B clients' Full Service Maintenance (FSM) agreements with Emergency Communication Devices (ECDs), encompassing over 930…

Dow’s Daily Performance and Market Analysis

The Dow Jones Industrial Average (DJIA) showed considerable volatility today, reacting to various economic data and company earnings announcements. Investors are closely monitoring the DJIA as a key indicator of U.S. economic health. The index, encompassing 30 major corporations, experienced a blend of gains and losses throughout the trading session.…

NMPA Approves BioRay’s BR111, a Novel ROR1-Targeting ADC, for Clinical Trials “`

SHANGHAI, February 10, 2025 — BioRay Pharmaceutical Co., Ltd. announced on December 19, 2024, that the National Medical Products Administration (NMPA) has approved its clinical trial application for BR111, a novel, self-developed Class 1 therapeutic biologic. BR111, an antibody-drug conjugate (ADC), targets dual ROR1 epitopes to treat ROR1-positive hematologic malignancies…

Palantir’s Stock: Future Outlook

Palantir Technologies (NYSE:PLTR), a leading data analytics firm serving government and commercial clients, has significantly expanded its client base and product offerings in recent years. Several factors will likely shape Palantir's stock performance in the coming year. A key focus for Palantir is its continued commercial sector growth. While government…